Dr. Paul R. Fortin, MD, MPH, FRCPC holds the Tier 1 Canada Research Chair in Systemic Autoimmune Rheumatic Diseases, is Professor at Laval University, and Clinical Investigator at the CHU Research Center of Quebec – Laval University. He obtained his medical degree from Laval University and is a graduate of McGill University in rheumatology. He then obtained a Master’s in Public Health from Harvard University’s School of Public Health.

Dr. Fortin is working to better understand the bio-psycho-social impact of systemic autoimmune rheumatic diseases (SARD), such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis, inflammatory myositis, and antiphospholipid syndrome (APS). He is particularly interested in the development of interventions for the treatment of SLE, RA, and APS.

His methodological interests are the development and validation of diagnostic and prognostic tests, new treatments, and new ways to measure the impact of these treatments on the health status of the patient, and on the levels of activity or harm of the disease within SARDs. His other methodological interests include developing healthy lifestyle habits for people with SARD, and measuring the impact of patient knowledge.

Since 2011, Dr. Fortin has been working on the creation and establishment of a new computerized database and biobank that enables the collection of informative biospecimens and clinical data relevant to the study of SARDs. This biobank and database now has more than 13,000 biospecimens, from over 250 people, and has already contributed to translational and clinical research projects, as well as two projects funded by the Canadian Institutes of Health Research.

Dr. Fortin received the Canadian Rheumatology Association (CRA) Young Investigator Award in 1999, the Kirkland Scholar Award in 2008, and the prestigious Research Achievement Award from The Arthritis Society of Canada (2007- 2012). In 2010, he received the Lupus Ontario Hope Award for his outstanding leadership in improving the lives of people with lupus. In May 2015, he received the Jeffrey Shiroky Research Award for his clinical research achievements in rheumatology.

CHUL
2705, boulevard Laurier
T0-97
Québec, Québec
Canada G1V 4G2
+1 418-654-2142
Paul.Fortin@crchudequebec...

Latest news

369 entries « ‹ 1 of 37 › »

Zuo Y, Navaz S, Tsodikov A, Kmetova K, Kluge L, Ambati A, Hoy CK, Yalavarthi S, de Andrade D, Tektonidou MG, Sciascia S, Pengo V, Ruiz-Irastorza G, Belmont HM, Gerosa M, Fortin PR, de Jesus GR, Branch DW, Andreoli L, Rodriguez-Almaraz E, Petri M, Cervera R, Willis R, Karp DR, Li QZ, Cohen H, Bertolaccini ML, Erkan D, Knight JS,

Anti-NET antibodies in antiphospholipid antibody-positive patients: Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository

Journal Article

Arthritis Rheumatol, 2023.

Abstract | Links:

Clarke AE, Hanly JG, Urowitz MB, St Pierre Y, Gordon C, Bae SC, Romero-Diaz J, Sanchez-Guerrero J, Bernatsky S, Wallace DJ, Isenberg DA, Rahman A, Merrill JT, Fortin PR, Gladman DD, Bruce IN, Petri M, Ginzler EM, Dooley MA, Ramsey-Goldman R, Manzi S, Jönsen A, Alarcón GS, Van Vollenhoven RF, Aranow C, Mackay M, Ruiz-Irastorza G, Lim SS, Inanc M, Kalunian KC, Jacobsen S, Peschken CA, Kamen DL, Askanase A, Farewell V

Assessing the Costs of Neuropsychiatric Disease in the Systemic Lupus International Collaborating Clinics Cohort Using Multistate Modeling

Journal Article

Arthritis Care Res (Hoboken), 2023.

Abstract | Links:

Hazlewood GS, Colmegna I, Hitchon C, Fortin PR, Bernatsky S, Clarke AE, Mosher D, Wilson T, Thomas M, Barber CEH, Harrison M, Bansback N, Proulx L, Richards DP, Kaplan GG

Preferences for COVID-19 Vaccination in People With Chronic Immune-Mediated Inflammatory Diseases

Journal Article

J Rheumatol, 2023.

Abstract | Links:

Barbacki A, Baron M, Wang M, Zhang Y, Stevens W, Sahhar J, Proudman S, Nikpour M, Man A,

Damage Trajectories in Systemic Sclerosis Using Group-Based Trajectory Modeling

Journal Article

Arthritis Care Res (Hoboken), 75 (3), 2023.

Abstract | Links:

Fortin PR, Neville C, Julien AS, Rahme E, Haroun V, Nimigon-Young J, Morrison AL, Eng D, Peschken CA, Vinet E, Hudson M, Smith D, Matsos M, Pope JE, Clarke AE, Keeling S, Avina-Zubieta JA, Rochon M, Da Costa D

Measuring the Impact of MyLupusGuide in Canada: Results of a Randomized Controlled Study

Journal Article

Arthritis Care Res (Hoboken), 75 (3), 2023.

Abstract | Links:

Almeida-Brasil CC, Hanly JG, Urowitz M, Clarke AE, Ruiz-Irastorza G, Gordon C, Ramsey-Goldman R, Petri MA, Ginzler EM, Wallace DJ, Bae SC, Romero-Diaz J, Dooley MA, Peschken C, Isenberg D, Rahman A, Manzi S, Jacobsen S, Lim SS, van Vollenhoven R, Nived O, Jönsen A, Kamen DL, Aranow C, Sánchez-Guerrero J, Gladman DD, Fortin PR, Alarcon GS, Merrill JT, Kalunian K, Ramos-Casals M, Steinsson K, Zoma A, Askanase AD, Khamashta M, Bruce IN, Inanc M, Lukusa L, Bernatsky S

Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine

Journal Article

Lupus Sci Med, 9 (1), 2022.

Abstract | Links:

Cardwell FS, Elliott SJ, Chin R, St Pierre Y, Choi MY, Urowitz MB, Ruiz-Irastorza G, Bernatsky S, Wallace DJ, Petri MA, Manzi S, Bae SC, Shin JM, Mak A, Cho J, Peschken CA, Ramsey-Goldman R, Fortin PR, Hanly JG, Pons-Estel BA, Nieto R, Askanase AD, Romero-Diaz J, Mosca M, Bruce IN, Rowbottom L, Mielczarek L, Tse K, Marion A, Cáhiz-González JC, Cattoni TG, Cornet A, Clarke AE

Health information use by patients with systemic lupus erythematosus (SLE) pre and during the COVID-19 pandemic

Journal Article

Lupus Sci Med, 9 (1), 2022.

Abstract | Links:

Erton ZB, K Leaf R, de Andrade D, Clarke AE, Tektonidou MG, Pengo V, Sciascia S, Ugarte A, Belmont HM, Gerosa M, Fortin PR, Lopez-Pedrera C, Atsumi T, Zhang Z, Cohen H, Ramires de Jesús G, Branch DW, Wahl D, Andreoli L, Rodriguez-Almaraz E, Petri M, Barilaro G, Zuo Y, Artim-Esen B, Willis R, Quintana R, Vendramini MB, Barber MW, Bertolaccini ML, Roubey R, Erkan D

Immunosuppression use in primary antiphospholipid antibody-positive patients: Descriptive analysis of the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository ("Registry")

Journal Article

Lupus, 31 (14), 2022.

Abstract | Links:

Becker YLC, Duvvuri B, Fortin PR, Lood C, Boilard E

The role of mitochondria in rheumatic diseases

Journal Article

Nat Rev Rheumatol, 18 (11), 2022.

Abstract | Links:

Michou L, Julien AS, Witteman HO, Légaré J, Ratelle L, Godbout A, Tardif J, Côté S, Boily G, Lui R, Ikic A, Trudeau J, Tremblay JL, Fortin I, Bessette L, Chetaille AL, Fortin PR

Measuring the impact of an educational intervention in rheumatoid arthritis: An open-label, randomized trial

Journal Article

Arch Rheumatol, 37 (2), 2022.

Abstract | Links:

369 entries « ‹ 1 of 37 › »
Signaler des ajouts ou des modifications

Active projects

  • Canada research chair in Innovate Systemic Autoimmune Rheumatic Disease, from 2019-07-01 to 2026-06-30
  • COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune Diseases / La réponse immunitaire au vaccin contre la COVID-19 chez des patients immunosupprimés en raison de maladies auto-immunes, from 2021-03-16 to 2023-03-31
  • FcgRI as a potential therapeutic target in inflammatory arthritis, from 2022-01-01 to 2025-03-31
  • Hydroxychloroquine in systemic lupus, from 2018-04-01 to 2023-03-31
  • Maladies Rhumatismales Autoimmunes Systémiques (MRAS) , from 2020-12-15 to 2023-03-31
  • Megakaryocyte: a new player in systemic lupus erythematosus, from 2022-09-01 to 2023-08-31
  • Platelets and neutrophils: the two culprits mediating pain in inflammatory arthritis, from 2020-04-01 to 2025-03-31
  • Role of autotaxin bound to platelet-derived microparticles to development of vascular damage in arthritis., from 2015-07-01 to 2023-03-31
  • Role of phosphatidylserine-specific phospholipase A1 (PLA1A) in the pathogenesis of rheumatic diseases, from 2023-01-01 to 2025-12-31
  • Safety immUnogenicity of Covid-19 vaCcines in systEmic immunE mediated inflammatory Diseases (SUCCEED) , from 2021-04-01 to 2023-03-31
  • The impact of antimalarial drugs in arthritis patients exposed to SARS-CoV-2- the CoVIRAL project, from 2020-04-01 to 2023-03-31

Recently finished projects

  • Booster dose of mRNA SARS-CoV-2 vaccine vs non mRNA vaccine for people living with systemic autoimmune rhumatic diseases without adequate humoral response post standard mRNA vaccination, from 2021-12-01 to 2022-11-30
  • CompreHensive Analysis of Mitochondria in Pathogenesis of SLE (CHAMPS), from 2021-09-01 to 2022-08-31
  • Mapping anti-mitochondrial antibodies in systemic lupus erythematosus, from 2019-04-01 to 2022-03-31
  • New statistical methods for cohort studies of adverse effects of medications, from 2016-07-01 to 2021-06-30
  • Platelets and neutrophils: the two culprits mediating pain in inflammatory arthritis, from 2020-01-01 to 2022-12-31
  • Profil moléculaire sanguin de patientes souffrant de lupus, from 2019-04-01 to 2021-03-31
  • Projet de recherche sur les maladies arthritiques, from 2019-12-01 to 2021-11-30
  • Understanding the pathogenesis of COVID-19, from 2020-03-01 to 2023-02-28
  • Unité support du Québec: Un soutien pour la recherche axée sur le patient, from 2014-04-01 to 2022-03-31
Data provided by the Université Laval research projects registery